Cargando…

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

OBJECTIVE. To determine whether a non-platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma. METHODS. Gynecologic Oncology Group protocol 240 is a phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tewari, Krishnansu S., Sill, Michael W., Birrer, Michael J., Penson, Richard T., Huang, Helen, Moore, David H., Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., Monk, Bradley J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286827/ https://www.ncbi.nlm.nih.gov/pubmed/36898292 http://dx.doi.org/10.1016/j.ygyno.2023.01.010

Ejemplares similares

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study
por: Seamon, Leigh G, et al.
Publicado: (2018)

Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
por: Vukovic, V., et al.
Publicado: (1997)

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
por: Santin, Alessandro D., et al.
Publicado: (2020)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology
por: Wolford, Juliet E., et al.
Publicado: (2017)

Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
por: Santin, Alessandro D., et al.
Publicado: (2020)

Updates on drug discovery in ovarian cancer
por: Gibson, Steven J, et al.
Publicado: (2014)

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
por: Pitiyarachchi, Omali, et al.
Publicado: (2022)

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
por: Penson, R T, et al.
Publicado: (2005)

Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials
por: Hallemeier, Christopher L., et al.
Publicado: (2023)

The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
por: Mainwaring, P. N., et al.
Publicado: (1997)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology
por: Gensheimer, Michael F., et al.
Publicado: (2020)

Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study
por: Casablanca, Yovanni, et al.
Publicado: (2022)

Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies
por: Tewari, Krishnansu S.
Publicado: (2016)

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
por: Tewari, Krishnansu S.
Publicado: (2019)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery
por: Chetvertkov, Mikhail, et al.
Publicado: (2020)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
por: Brueseke, Taylor J, et al.
Publicado: (2013)

Response to Harper and De Mars, HPV vaccines: A review of the first decade
por: Ramondetta, Lois
Publicado: (2017)

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study
por: Goodfellow, Paul J., et al.
Publicado: (2015)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease
por: Yang, Dehua, et al.
Publicado: (2017)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

NRG1 fusions in breast cancer
por: Howarth, Karen D., et al.
Publicado: (2021)

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
por: Léger, F, et al.
Publicado: (2004)

Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer
por: Kuehl, Philip J., et al.
Publicado: (2021)

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
por: Chiappori, Alberto A., et al.
Publicado: (2016)

Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience
por: Upadhyayula, Pavan S., et al.
Publicado: (2020)

Expression of NRG1 and its receptors in human bladder cancer
por: Forster, J A, et al.
Publicado: (2011)

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways
por: Birrer, Michael J., et al.
Publicado: (2022)

Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey()
por: Cook, Elise D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uqqn9fj1mvd0fps8qa3r91v60b